Acquired colour deficiency in patients with Parkinson’s disease

The blue cone pathway is reported to be affected early in Parkinson’s disease (PD) and acquired type three (tritan) defects may occur. Sixty-one patients attending a treatment and rehabilitation centre for PD were examined with clinical colour vision tests. Seven of 13 patients, for whom the diagnos...

Full description

Saved in:
Bibliographic Details
Published in:Vision research (Oxford) 1998-11, Vol.38 (21), p.3421-3426
Main Authors: Birch, Jennifer, Kolle, Renate U, Kunkel, M, Paulus, Walter, Upadhyay, Pushpa
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biological and medical sciences
Clinical tests
Color Perception Tests
Color Vision Defects - etiology
Colour deficiency
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Female
Humans
Male
Medical sciences
Middle Aged
Neurology
Parkinson Disease - complications
Parkinson Disease - diagnosis
Parkinsons disease
Tritan tests
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The blue cone pathway is reported to be affected early in Parkinson’s disease (PD) and acquired type three (tritan) defects may occur. Sixty-one patients attending a treatment and rehabilitation centre for PD were examined with clinical colour vision tests. Seven of 13 patients, for whom the diagnosis of PD was equivocal or who had other medical conditions, were identified as having tritan colour deficiency. Results for the remaining 44 PD patients were compared with 40 age matched controls. Ten PD patients (22.7%) had tritan defects. Tritan defects were not found in the control group but performance on some tests was age related. We conclude that clinical tests for tritan colour deficiency are unlikely to be helpful in identifying PD.
ISSN:0042-6989
1878-5646
DOI:10.1016/S0042-6989(97)00398-2